186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
Pain palliation with bone-seeking radiopharmaceuticals is an effective treatment modality in patients with advanced metastatic bone cancer. Several studies have shown encouraging clinical results of palliative therapy using 186Re-HEDP, with an overall reported response rate of +/-71% for painful osseous metastasized prostate and breast cancer patients. 186Re-HEDP is a very potential isotope with numerous advantageous characteristics for this purpose. Myelosuppressive toxicity is limited and reversible, which makes repetitive treatment safe. However, individual studies are difficult to compare, and are hampered by the numerous and different methods used to assess clinical response. Standardized clinical response assessment using the objective multi-dimensional pain evaluation model should therefore be implemented.
Han
S H
SH
Department of Nuclear Medicine, University  Medical Center Utrecht, The Netherlands.
De Klerk
J M
JM
Zonnenberg
B A
BA
Tan
S
S
Van Rijk
P P
PP
D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010148:Intractable Pain / Q000532:radiotherapy*; D010166:Palliative Care; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D012211:Rhenium / Q000627:therapeutic use; D014004:Tin Radioisotopes / Q000627:therapeutic use*
D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D014004:Tin Radioisotopes; C064573:rhenium-186(tin)etidronate; D012211:Rhenium; D012968:Etidronic Acid